LXRX
Lexicon Pharmaceuticals, Inc.
stock NASDAQ

Market Open

Jul 10, 2025 11:49:22 AM EDT

1.18USD+10.748%(+0.11)2,713,149

1.18Bid 1.20Ask 0.02Spread

Pre-market

Jul 10, 2025 9:24:30 AM EDT

1.07USD-0.009%(0.00)15,320

After-hours

Jul 9, 2025 4:56:30 PM EDT

1.08USD+1.399%(+0.01)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 13, 2022

09:00AM EST NDA submitted for sotagliflozin in heart failure with an expected launch in 2H 2022, if approved GlobeNewswire Inc

Jan 4, 2022

04:05PM EST Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicons chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. ET. GlobeNewswire Inc

Dec 31, 2021

06:05AM EST A Peek Into The Markets: US Stock Futures Edge Lower On Final Trading Day Of 2021 Benzinga

Dec 30, 2021

04:08PM EST Lexicon Submits New Drug Application For Sotagliflozin For Treatment Of Heart Failure In Adults With Type 2 Diabetes Benzinga

04:05PM EST Lexicon Submits New Drug Application for Sotagliflozin for the GlobeNewswire Inc

Nov 15, 2021

03:03PM EST Lexicon's Sotagliflozin Shows Benefits in Heart Failure, Blood Glucose Control Benzinga

Nov 14, 2021

08:35AM EST Post hoc analysis of pooled clinical data from the SOLOIST and SCORED trials supporting benefit of sotagliflozin presented at the virtual American Heart Association Scientific Sessions 2021, including: GlobeNewswire Inc

Nov 9, 2021

11:46AM EST New Analysis To Be Presented At The American Heart Association Scientific Sessions 2021 Evaluating Cardiovascular Benefits Across Baseline Kidney Function Benzinga

08:00AM EST Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 outcomes studies will be presented at the virtual American Heart Association Scientific Sessions 2021. GlobeNewswire Inc

Nov 3, 2021

05:23PM EDT Lexicon Pharmaceuticals Q3 EPS $(0.16) Beats $(0.18) Estimate, Sales $23.00K Down From $6.63M YoY Benzinga

05:18PM EDT Recap: Lexicon Pharmaceuticals Q3 Earnings Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

Sep 15, 2021

08:00AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicons president and chief executive officer, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 21, 2021 at 10:45 a.m. ET. GlobeNewswire Inc

Aug 30, 2021

07:00AM EDT New guidelines from the European Society of Cardiology recommend addition of SGLT inhibitors to standard of care for patients with acute and chronic heart failure. GlobeNewswire Inc

Aug 23, 2021

06:10AM EDT Lexicon's Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials Benzinga

06:09AM EDT Rapid benefit of sotagliflozin supported by data from the SOLOIST and SCORED trials presented at ESC Congress 2021 - The Digital Experience, including: GlobeNewswire Inc

Aug 16, 2021

10:31AM EDT Overview Of Value Stocks In The Healthcare Sector Benzinga

Aug 6, 2021

04:14PM EDT Lexicon S-3 Shows Registration For $200M Mixed Securities Shelf Offering Benzinga

Jul 30, 2021

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

07:21AM EDT Lexicon Pharmaceuticals: Q2 Earnings Insights Benzinga

07:10AM EDT Lexicon Pharmaceuticals Q2 EPS $(0.13) Beats $(0.16) Estimate, Sales $200.00K Beat $10.00K Estimate Benzinga

07:01AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021. GlobeNewswire Inc

07:00AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2021 and provided an update on key milestones. GlobeNewswire Inc

04:13AM EDT Earnings Scheduled For July 30, 2021 Benzinga

Jul 21, 2021

07:06AM EDT Lexaria Highlights VIRAL-A20-3 STudy Results Showing 'Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects' Benzinga

Jun 25, 2021

08:00AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be a symposium highlighting sotagliflozin followed by a live video question and answer period during the American Diabetes Associations 81st Scientific Sessions being held virtually June 25, 2021 through June 29, 2021: GlobeNewswire Inc

May 26, 2021

04:15PM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicons president and chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET. GlobeNewswire Inc

May 13, 2021

04:15PM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be two virtual presentations highlighting sotagliflozin during the American College of Cardiologys 70th Annual Scientific Session (ACC.21) being held May 15, 2021 through May 17, 2021: GlobeNewswire Inc

May 6, 2021

05:36PM EDT Recap: Lexicon Pharmaceuticals Q1 Earnings Benzinga

05:14PM EDT Lexicon Pharmaceuticals Q1 EPS $(0.15) Beats $(0.16) Estimate, Sales $27.00K Miss $1.68M Estimate Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 8, 2021

04:35PM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicons executive vice president, corporate and administrative affairs and chief financial officer, will participate in a live fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 a.m. ET. GlobeNewswire Inc

Mar 10, 2021

04:10PM EST Lexicon Pharmaceuticals Q4 EPS $(0.04) Beats $(0.28) Estimate, Sales $200.00K Beat $110.00K Estimate Benzinga

04:10PM EST Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2020 and provided an update on key milestones. GlobeNewswire Inc

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

04:04AM EST Earnings Scheduled For March 10, 2021 Benzinga

Mar 9, 2021

10:24AM EST Earnings Preview: Lexicon Pharmaceuticals Benzinga

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 4, 2021

04:05PM EST Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2020 financial results on Wednesday, March 10, 2021 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. GlobeNewswire Inc

Feb 3, 2021

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

Jan 29, 2021

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 29, 2021 Benzinga

08:55AM EST Wedbush Downgrades Lexicon Pharmaceuticals to Neutral, Raises Price Target to $8 Benzinga

07:40AM EST JP Morgan Upgrades Lexicon Pharmaceuticals to Neutral, Announces $7 Price Target Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 14, 2021

02:33PM EST Mid-Afternoon Market Update: Dow Rises 75 Points; Acacia Communications Shares Spike Higher Benzinga

12:27PM EST Mid-Day Market Update: Volt Information Sciences Drops After Q4 Results; Lexicon Pharmaceuticals Shares Jump Benzinga

10:27AM EST Mid-Morning Market Update: Markets Open Higher; Delta Air Lines Posts Wider-Than-Expected Loss Benzinga

10:26AM EST Shares of Lexicon Pharmaceuticals, Inc. (LXRX) are currently gaining over 35% after the company said it received a regulatory feedback that clears a key hurdle for partnership discussions around sotagliflozin in heart failure. RTTNews

08:16AM EST Lexicon Gets FDA Feedback That Results Of SOLOIST, SCORED Phase 3 Studies Can Support NDA Submission RTTNews

08:00AM EST Lexicon Pharmaceuticals Provides Regulatory Update on GlobeNewswire Inc

Jan 6, 2021

08:00AM EST Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicons president and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 2:50 p.m. ET. GlobeNewswire Inc

Dec 31, 2020

08:08AM EST Lexicon Begins Patient Dosing In RELIEF-PHN 1 Study Of LX9211 For Post-herpetic Neuralgia RTTNews

08:01AM EST Lexicon Pharma Reports Commencement Of Dosing In Phase 2 Study Of LX9211 In Post-Herpetic Neuralgia Benzinga

08:00AM EST Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of post-herpetic neuralgia. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1). GlobeNewswire Inc

Dec 20, 2020

07:19AM EST Notable Insider Buys of the Past Week: Mylan, Sonabank, Steak 'n Shake, U-Haul And More Benzinga

Dec 16, 2020

04:52PM EST Wunong Net Technology Co. Ltd. (WNW) - Shares of the Chinese e-commerce company gained nearly 20% in after hours trading on top of 400% surge in regular trading on Wednesday, its second day of trading since its IPO. On Tuesday, its first day of trading, Wunong shares rose 141%. The Shenzhen-based company had raised $30 million in its IPO. RTTNews

04:06PM EST Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience; Lexicon Will Receive An Upfront Payment And Is Eligible To Receive Milestone Payments Totaling Up To $5.3M In The Aggregate Benzinga

04:05PM EST Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience GlobeNewswire Inc

Dec 11, 2020

03:08PM EST Lexicon Pharmaceuticals shares were trading higher after the company announced it has received Fast Track designation from the FDA for the development of LX9211 in diabetic peripheral neuropathic pain. Benzinga

08:16AM EST Lexicon Pharmaceuticals, Inc. (LXRX) has received Fast Track designation from the FDA for the development of LX9211 in diabetic peripheral neuropathic pain. LX9211 is a potent, orally delivered, selective small molecule inhibitor of adapter-associated kinase 1 (AAK1). RTTNews

08:10AM EST Lexicon Receives Fast Track Designation From FDA For Development Of LX9211 RTTNews

08:09AM EST Lexicon Plans Direct Offering Of 20.31 Mln Shares At $3.20 Per Share RTTNews

08:02AM EST Lexicon Pharma Prices 20.3M Shares At $3.20/Share Benzinga

08:02AM EST Lexicon Announces Offering of Common Stock GlobeNewswire Inc

07:38AM EST Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain. GlobeNewswire Inc

07:38AM EST Lexicon Pharma Reports Fast Track Designation For LX9211 For Diabetic Peripheral Neuropathic Pain Benzinga

Dec 8, 2020

02:31PM EST Mid-Afternoon Market Update: Dow Jumps 150 Points; Stitch Fix Shares Gain On Upbeat Q1 Earnings Benzinga

12:28PM EST Mid-Day Market Update: US Stocks Turn Positive; Arcturus Therapeutics Shares Plunge Benzinga

09:36AM EST Benzinga's Top Upgrades, Downgrades For December 8, 2020 Benzinga

07:51AM EST Citigroup Upgrades Lexicon Pharmaceuticals to Buy, Raises Price Target to $6 Benzinga

Nov 23, 2020

12:19PM EST The November Market Grinds Along Benzinga

Nov 19, 2020

05:53AM EST What's moving these stocks in the pre-market hours today? RTTNews

Nov 18, 2020

09:39AM EST Lexicon Pharmaceuticals shares were trading higher after Gabelli & Co upgraded the stock from Hold to Buy. Benzinga

06:14AM EST Gabelli & Co. Upgrades Lexicon Pharmaceuticals to Buy Benzinga

Nov 17, 2020

02:46PM EST Mid-Afternoon Market Update: Nasdaq Turns Positive; Cinedigm Shares Slide Benzinga

12:37PM EST Mid-Day Market Update: Sequential Brands Gains After Q3 Results; Brainstorm Cell Therapeutics Shares Plunge Benzinga

11:00AM EST Why Lexicon Pharmaceuticals Stock Is Trading Higher Today Benzinga

10:26AM EST Yahoo Finance Trending Stocks For Tuesday, Nov. 17, 2020: TSLA, FCEL, COST, HD, PLUG, WMT, CVS, ABBV, WBA, GDRX, SE, VTRS, AMZN, LXRX, CTIB, BCLI, WWR, DQ, MOGO, SQBG, BLNK, RAD, MCK, RIDE, BMY, TMUS, RMED, MAPT, IQ Benzinga

Nov 16, 2020

10:02PM EST Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo. GlobeNewswire Inc

08:00AM EST Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conference: GlobeNewswire Inc

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 3, 2020

07:38AM EST The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure Benzinga

Nov 2, 2020

09:10AM EST Stocks Trading Near 52-Week Lows Before Open On Monday, Nov. 2, 2020: CLSN, MRTN, UTSI, LXRX, TTNP, ORTX, ARTL, PEI, CBL Benzinga

Oct 30, 2020

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

Oct 29, 2020

08:52AM EDT Stocks Trading Near 52-Week Lows Before Open On Thursday, Oct. 29, 2020: WORX, OXY, HYLN, LXRX, TS, BTU, TCDA, GILD, ETTX, PBF, TEF, EURN Benzinga

08:02AM EDT Lexicon Pharmaceuticals: Q3 Earnings Insights Benzinga

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

06:50AM EDT Lexicon Pharmaceuticals Q3 EPS $(0.43) Misses $0.26 Estimate, Sales $6.63M Miss $16.87M Estimate Benzinga

06:00AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2020 and provided an update of key milestones. GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 27, 2020

08:25AM EDT The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga

08:00AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2020 financial results on Thursday, October 29, 2020 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a clinical update. GlobeNewswire Inc

Oct 22, 2020

07:52AM EDT The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat Benzinga

Sep 24, 2020

05:38AM EDT Lexicon Pharmaceuticals Announced Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness Benzinga

Sep 23, 2020

06:43PM EDT Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible GlobeNewswire Inc

Sep 14, 2020

09:46AM EDT A Look Into Healthcare Sector Value Stocks Benzinga

Sep 8, 2020

04:05PM EDT Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera GlobeNewswire Inc

Sep 4, 2020

10:37AM EDT Lexicon Pharmaceuticals shares are trading higher after the company announced the commencement of a patient dosing in the RELIEF-DPN-1 Phase 2 clinical study of its LX9211 in patients with diabetic peripheral neuropathic pain. Benzinga

08:04AM EDT Lexicon Pharma Begins Patient Dosing In RELIEF-DPN-1 Phase 2 Clinical Study Of LX9211 RTTNews

08:03AM EDT Lexicon Pharmaceuticals Announces Commencement Of Patient Dosing In RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 In Patients With Diabetic Peripheral Neuropathic Pain Benzinga

08:00AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing with blinded study drug in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1). GlobeNewswire Inc

Sep 3, 2020

06:00PM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conferences: GlobeNewswire Inc

Aug 24, 2020

11:36AM EDT A Look Into Healthcare Sector Value Stocks Benzinga

Aug 10, 2020

11:52AM EDT 5 Value Stocks To Watch In The Healthcare Sector Benzinga

Aug 4, 2020

06:18AM EDT Lexicon Pharmaceuticals Intends To Implement Reduction In Force, Which Will Reduce Workforce By About 50% Related To Tersera Therapeutics Agreement Benzinga

Aug 3, 2020

09:35AM EDT Lexicon Pharmaceuticals shares are trading higher. The Company last week announced it will sell Xermelo to GTCR and TerSera Therapeutics for an upfront purchase price of approximately $159 million along with potential milestone payments. NOTE: GTCR issued a press release today detailing the acquisition. Benzinga

07:33AM EDT GTCR And TerSera Therapeutics Issue Press Release Detailing Definitive Agreement To Acquire Xermelo From Lexicon Pharmaceuticals For $159M Plus Potential Milestones. BZ NOTE: Lexicon Announced Sale Of Xermelo Last Week Benzinga

07:29AM EDT GTCR And TerSera Therapeutics Enter Definitive Agreement To Acquire Xermelo From Lexicon Pharmaceuticals For $159M Plus Potential Milestones Benzinga

07:27AM EDT TerSera Therapeutics Enters Definitive Agreement To Acquire Product Xermelo From Lexicon RTTNews

07:25AM EDT GTCR and TerSera Therapeutics Announce Acquisition of Xermelo PR Newswire

Jul 30, 2020

08:44AM EDT Lexicon Says Is Realigning Business Around Research And Development Assets, With Focus On Phase 2 LX9211 Neuropathic Pain Program Benzinga

07:21AM EDT Lexicon Pharma Shares To Resume Trade At 7:45 a.m. EDT Benzinga

07:21AM EDT UPDATE: Lexicon May Receive Added Development, Regulatory, Sales Milestone Payments Of Up To $65M Benzinga

07:20AM EDT Lexicon Pharma Reports Deal With TerSera Therapeutics For Sale Of XERMELO For $159M In Cash Benzinga

07:18AM EDT Lexicon Pharmaceuticals Q2 EPS $(0.65) Misses $(0.61) Estimate, Sales $9.16M Beat $8.83M Estimate Benzinga

07:15AM EDT Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain GlobeNewswire Inc

07:10AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicons rights, title and interest in XERMELO (telotristat ethyl). GlobeNewswire Inc

07:01AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2020. GlobeNewswire Inc

06:59AM EDT Lexicon Pharma Shares Halted News Pending Benzinga

04:06AM EDT Earnings Scheduled For July 30, 2020 Benzinga

Jul 27, 2020

01:54AM EDT 5 Value Stocks In The Healthcare Sector Benzinga

Jul 23, 2020

07:00AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2020 financial results on Thursday, July 30, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a business update. GlobeNewswire Inc

Jul 21, 2020

07:09AM EDT Lexicon: All Four Phase 3 Sotagliflozin Studies Met Primary Objectives Of Lowering A1C In Patients With Type 2 Diabetes RTTNews

07:05AM EDT Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies In Type 2 Diabetes Benzinga

07:00AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS. The final results of these studies will be preserved for upcoming medical congresses and publications. GlobeNewswire Inc

Jul 20, 2020

07:00AM EDT Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that four posters highlighting XERMELO (telotristat ethyl) will be presented at the virtual Cholangiocarcinoma Foundation Annual Conference (July 22-24). GlobeNewswire Inc